Products
Pharmaceutical
Psilocybin, Ibogaine,
and other compounds
Products
Pharmaceutical
Psilocybin, Ibogaine,
and other compounds
PsyLabs develops and manufactures naturally derived psychedelic active pharmaceutical ingredients (APIs), botanical extracts, and advanced formulations designed for research, clinical trials, and therapeutic development.
Proven Global Export Capability
PsyLabs has established a strong international footprint through the successful export of psychedelic products to Canada, the United Kingdom, Portugal, Australia, and Slovenia.
These exports demonstrate the company’s ability to consistently meet the rigorous regulatory, quality, and compliance requirements of diverse global markets.
By supplying pharmaceutical-grade products to both medical and research sectors, PsyLabs has validated its manufacturing excellence and positioned itself as a trusted partner within the rapidly expanding global psychedelic therapeutics industry.
Proven Global Export Capability
PsyLabs has established a strong international footprint through the successful export of psychedelic products to Canada, the United Kingdom, Portugal, Australia, and Slovenia.
These exports demonstrate the company’s ability to consistently meet the rigorous regulatory, quality, and compliance requirements of diverse global markets.
By supplying pharmaceutical-grade products to both medical and research sectors, PsyLabs has validated its manufacturing excellence and positioned itself as a trusted partner within the rapidly expanding global psychedelic therapeutics industry.
Psilocybin
NPX-5
The pipeline currently focuses on psilocybin and ibogaine-based products, while the company also maintains licences and R&D capability for additional psychedelic compounds including mescaline and DMT
Derived from controlled cultivation of Psilocybe cubensis, NPX-5 delivers consistent, reproducible dosing in both bulk powder and precision capsule formats, bridging the gap between natural extracts and pharmaceutical-grade development. NPX-5 5mg psilocybin capsules have been approved by the Therapeutic Goods Administration (TGA) for a phase 2b clinical trial in Australia.
Key product formats:
Formats include
Applications
Key product formats:
Formats include
Applications
Ibogaine
PsyLabs’ ibogaine platform is positioned as a pharmaceutical-grade, research-focused product line designed to support clinical trials, special access programs and early-stage therapeutic development.
The company manufactures naturally derived ibogaine products to pharmaceutical standards, with a strong emphasis on quality assurance, analytical validation and secure global supply.
Key product formats:
Other Neurotherapeutics in Development
PsyLabs is licensed to work with additional psychedelic compounds including:
The company actively seeks collaborative partnerships for research, formulation development and clinical translation in these compounds.
